Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Moderna, Inc. (NASDAQ:MRNA) have reached a stipulation in their ongoing ...

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...

With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...

Camp4 Therapeutics Inc., a Cambridge biotech that has already struck deals with Biogen Inc. and Alnylam Pharmaceuticals Inc., ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,295.68 today based on a ...

Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.

Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...

In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), ...

Alnylam Pharmaceuticals (ALNY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...

US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated measures of disease progression across multiple ...